Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma.
Zhaojuan WangYujie QinXuxia ChaiLina LuPing XueRunrun LuChengrui MiaoHaimei MaXiaoyi HuJiaxi YaoPublished in: Cancer control : journal of the Moffitt Cancer Center (2023)
In patients with mRCC treated with sunitinib and sorafenib, an NLR <2.85 and MLR <.30 was associated with superior PFS and OS, which may be related to the reduced lymphocytic infiltration of tumors.